Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1038-1044

  Romano, A ^a   Chiarenza, A ^b   Consoli, U ^c   Conticello, C ^d   Forte, S ^e   Uccello, G ^a   Vetro, C ^a   Cavalli, M ^a   Coppolino, F ^f   Palumbo, G A ^b   Di Raimondo, F ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b Hematology Division   (Italy)

^c ARNAS Garibaldi   (Italy)

^d Mediterranean Institute of Oncology   (Italy)

^e IOM Ricerca srl   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

Intravenous therapy; Multiple myeloma; Salvage therapy

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875578738     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds531     Document Type: Article

References (33)

1. Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000-2010. Clin Lymphoma Myeloma Leuk 2010; 10: 424-442.
2. Richardson PG, Laubach J, Mitsiades CS et al. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011; 154(6): 755-762.
3. Musto P, D'Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs 2007; 16: 1467-1487.
4. 2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. Eur J Haematol 1989; 42: 233-237.
5. Tsakanikas S, Papanastasiou K, Stamatelou M et al. Intermediate dose of intravenous melphalan in advanced multiple myeloma. Oncology 1991; 48: 369-371.
6. 2) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002; 15: 684-689.
7. Palumbo A, Bringhen S, Bruno B et al. Melphalan 200mg/m(2) versus melphalan 100mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115: 1873-1879.
8. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
9. Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011; 25: 689-696.
10. Facon T, Mary JY, Pégourie B et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for highdose therapy. Blood 2006; 107: 1292-1298.
11. Shustik C, Belch A, Robinson S et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007; 136: 203-211.
12. Palumbo A, Avonto I, Bruno B et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006; 76: 273-277.
13. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
14. Ma MH, Yang HH, Parker K et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
15. Teicher BA, Ara G, Herbst R et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
16. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
17. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259-2266.
18. Harousseau JL, Palumbo A, Richardson PG et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; 116: 3743-3750.
19. Sviland L, Leggat H, Harris AL et al. Short course intermediate dose intravenous melphalan therapy in myeloma-relation to early emergence of drug resistance (phase II study). Acta Haematol 1987; 78: 233-238.
20. Osterborg A, Ehrsson H, Eksborg S et al. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Cancer Clin Oncol 1989; 25: 899-903.
21. Ehrsson H, Eksborg S, Osterborg A et al. Oral melphalan pharmacokinetics- relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 1989; 6: 151-154.
22. Bosanquet AG, Gilby ED. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 1982; 18: 355-362.
23. Bäck H, Lindblad R, Rödjer S et al. Single-dose intravenous melphalan in advanced multiple myeloma. Acta Haematol 1990; 83: 183-186.
24. Rajkumar SV, Harousseau JL, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-4695.
25. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
26. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
27. Djulbegovic B. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol 2005; 18: 455-466.
28. Shimizu T, Saijo N. Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment. Nihon Rinsho 2003; 61: 937-942.
29. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
30. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
31. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28: 5101-5109.
32. Popat R, Oakervee H, Williams C et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 2009; 144: 887-894.
33. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.